FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-κB signaling

Oncogene

Volumn 31, Issue 45, 2012, Pages 4798-4802

  Wang, J ^a   Ray, P S ^a   Sim, M S ^a   Zhou, X Z ^b   Lu, K P ^b   Lee, A V ^c   Lin, X ^d   Bagaria, S P ^a   Giuliano, A E ^a   Cui, X ^a,e  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Basal like breast cancer; FOXC1; NF B; p65 RelA; Pin1; Protein stability

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDYLPROLYL ISOMERASE PIN1; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR FOXC1; TRANSCRIPTION FACTOR RELA;

ARTICLE; BASAL LIKE BREAST CANCER; CANCER CELL; CANCER INVASION; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS, BASAL CELL; NF-KAPPA B; PEPTIDYLPROLYL ISOMERASE; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA;

EID: 84869088684     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.635     Document Type: Article

References (32)

1. Dairkee SH, Puett L, Hackett AJ. Expression of basal and luminal epitheliumspecific keratins in normal, benign, and malignant breast tissue. J Natl Cancer Inst 1988; 80: 691-695.
2. Wetzels RHW, Holland R, Haelst UJGMv, Lane EB, Leigh IM, Ramaekers FCS. Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. Am J Pathol 1989; 134: 571-579. (Pubitemid 19082851)
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
4. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9: R65.
5. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568-2581.
6. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502. (Pubitemid 43854964)
7. Seewaldt VL, Scott V. Images in clinical medicine. Rapid progression of basal-type breast cancer. N Engl J Med 2007; 356: e12. (Pubitemid 46513302)
8. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-271. (Pubitemid 43117611)
9. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008; 68: 989-997. (Pubitemid 351272216)
10. Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005; 14: 1108-1112. (Pubitemid 40656455)
11. Dejeux E, Ronneberg JA, Solvang H, Bukholm I, Geisler S, Aas T et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol Cancer 2010; 9: 68.
12. Ray PS, Wang J, Qu Y, Sim MS, Shamonki J, Bagaria SP et al. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res 2010; 70: 3870-3876.
13. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci U S A 2010; 107: 15449-15454.
14. Nishimura DY, Swiderski RE, Alward WL, Searby CC, Patil SR, Bennet SR et al. The forkhead transcription factor gene FKHL7 is responsible for glaucoma phenotypes which map to 6p25. Nat Genet 1998; 19: 140-147. (Pubitemid 28248794)
15. Kume T, Deng KY, Winfrey V, Gould DB, Walter MA, Hogan BL. The forkhead/winged helix gene Mf1 is disrupted in the pleiotropic mouse mutation congenital hydrocephalus. Cell 1998; 93: 985-996. (Pubitemid 28280792)
16. Mears AJ, Jordan T, Mirzayans F, Dubois S, Kume T, Parlee M et al. Mutations of the forkhead/winged-helix gene, FKHL7, in patients with Axenfeld-Rieger anomaly. Am J Hum Genet 1998; 63: 1316-1328. (Pubitemid 30418529)
17. Kidson SH, Kume T, Deng K, Winfrey V, Hogan BL. The forkhead/winged-helix gene, Mf1, is necessary for the normal development of the cornea and formation of the anterior chamber in the mouse eye. Dev Biol 1999; 211: 306-322. (Pubitemid 29343284)
18. Smith RS, Zabaleta A, Kume T, Savinova OV, Kidson SH, Martin JE et al. Haploinsufficiency of the transcription factors FOXC1 and FOXC2 results in aberrant ocular development. Hum Mol Genet 2000; 9: 1021-1032. (Pubitemid 30216007)
19. Moulder SL. Does the PI3K pathway play a role in basal breast cancer? Clin Breast Cancer 2010; 10: S66-S71.
20. Rexer BN, Ghosh R, Arteaga CL. Inhibition of PI3K and MEK: it is all about combinations and biomarkers. Clin Cancer Res 2009; 15: 4518-4520.
21. Lu S, Simin K, Khan A, Mercurio AM. Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance. Clin Cancer Res 2008; 14: 1050-1058. (Pubitemid 351302550)
22. Lee CW, Simin K, Liu Q, Plescia J, Guha M, Khan A et al. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res 2008; 10: R97.
23. Yamaguchi N, Ito T, Azuma S, Ito E, Honma R, Yanagisawa Y et al. Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines. Cancer Sci 2009; 100: 1668-1674.
24. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ, Sledge Jr GW. Constitutive activation of NF-kappaB during progression of breast cancer to hormoneindependent growth. Mol Cell Biol 1997; 17: 3629-3639. (Pubitemid 27281838)
25. Biswas DK, Iglehart JD. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol 2006; 209: 645-652. (Pubitemid 44665682)
26. Gershtein ES, Scherbakov AM, Platova AM, Tchemeris GY, Letyagin VP, Kushlinskii NE. The expression and DNA-binding activity of NF-kappaB nuclear transcription factor in the tumors of patients with breast cancer. Bull Exp Biol Med 2010; 150: 71-74.
27. Peng SL. Interplay between the NF-kappaB and forkhead transcription factors. Cell Death Differ 2005; 12: 699-701. (Pubitemid 40945977)
28. Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G et al. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 2003; 12: 1413-1426. (Pubitemid 38037011)
29. Lu KP. Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics. Cancer Cell 2003; 4: 175-180. (Pubitemid 37163831)
30. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V et al. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. Embo J 2001; 20: 3459-3472. (Pubitemid 32634353)
31. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10: 515-527. (Pubitemid 44854747)
32. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009; 15: 4649-4664.